Skip to content

Clinical Study on The Treatment of Androgenic Alopecia Caused by Dampness-heat Steaming Syndrome with Dansi Lotion

Clinical Study on The Treatment of Androgenic Alopecia Caused by Dampness-heat Steaming Syndrome with Dansi Lotion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109418
Enrollment
Unknown
Registered
2025-09-18
Start date
2023-09-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia

Interventions

Experimental group:Wash hair with Danse lotion
Control group:Patients received interventional treatment with externally applied 2% ketoconazole lotion (Triatop brand).

Sponsors

The Second Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Those who meet the criteria of diagnosis and syndrome type of androgen alopecia in Chinese and Western medicine; 2.Gender is not required, age 18-65 years, including 18 and 65 years; 3.Had not received hair loss treatment or used hair growth cosmetics within 3 months prior to study participation; 4.Had not received hair loss treatment or used hair growth cosmetics in the 3 months prior to study participation.

Exclusion criteria

Exclusion criteria: 1.Hair loss due to physical human factors, drug factors, endocrine disorders and other diseases, chemotherapy or postpartum and other factors; 2.congenital alopecia areata, total alopecia; 3.Combined with scalp injury or bacterial or fungal infection; 4.Liver and renal insufficiency; 5.Allergic to the drug and its ingredients; 6.Persons with mental illness or cognitive impairment; 7.Pregnant or lactating women; 8.Revious history of hair transplant surgery.

Design outcomes

Secondary

MeasureTime frame
Dermatology life quality index;Hair mirror examination indicators: number of hairs, variation rate of hair diameter, degree of scalp inflammation.;

Primary

MeasureTime frame
Efficacy index Q;

Countries

China

Contacts

Public ContactZhu Mingfang

The Second Affiliated Hospital of Hunan University of Chinese Medicine

26715858@qq.com+86 731 84917727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026